Historical ticker: BiomX Inc. changed its name to Tessera Defense and Homeland Security Inc. and began trading as HLSQ on September 11, 2026. PHGE news and SEC filings are retained here with their original names and dates. The profile below describes the earlier BiomX business.
BiomX Inc. (PHGE) news is centered on the company’s transition from a legacy phage therapy profile toward defense, security, critical infrastructure, and first-response technologies. Recent company announcements focus heavily on Zorronet, an AI defense technology subsidiary that develops command-and-control, computer vision, and autonomous surveillance systems.
PHGE news can include acquisition updates, material agreements, customer deployments, and operating details tied to Zorronet and DFSL. Zorronet-related coverage has included AI command-and-control software, secure on-premise and hybrid C5ISR deployments, mobile field-operator tools, and the use of cameras, sensors, drones, and IoT devices in integrated security environments.
Infrastructure and government-related items are also important for BiomX coverage. Company disclosures have discussed Zorronet’s work with Israel Railways, contracts with the Israel Defense Forces, and engagements involving government customers, Tier-1 OEMs such as Elbit Systems, and international clients. DFSL adds another news angle through LADAR-based detection systems for perimeter security, critical infrastructure, and counter-UAS markets.
BiomX news may also include SEC filing events, shareholder votes, governance changes, capital-structure disclosures, and operating results. Because the company has disclosed substantial doubt about its ability to continue as a going concern, financing and liquidity-related disclosures are also material to PHGE coverage. For investors tracking PHGE, the main news themes are defense technology acquisitions, operational deployments, critical infrastructure agreements, and the company’s remaining phage therapy background.
BiomX (NYSE:PHGE) will effect a 1-for-19 reverse stock split of its common stock, to trade on a split-adjusted basis when markets open on November 25, 2025. The company will file a Certificate of Amendment in Delaware and the new CUSIP after the split will be 09090D 509.
The split was approved by stockholders on October 16, 2025 and the Board fixed the final ratio on November 13, 2025. Outstanding shares are expected to be reduced from approximately 29,006,165 to approximately 1,526,640, with proportional adjustments to equity awards, warrants, convertible preferred stock and plan share pools. No fractional shares will be issued; holders entitled to fractions will be rounded up to the next whole share. Recordholders with certificates will receive instructions from Continental Stock Transfer & Trust Company; street-name holders need take no action.
BiomX (NYSE:PHGE) reported third quarter 2025 results and clinical updates on Nov 12, 2025. Key clinical points: positive FDA feedback on BX011 (S. aureus in diabetic foot infections) with a planned Phase 2a and FDA guidance outlining potential Phase 3 pathways for BX004 (P. aeruginosa in cystic fibrosis). The FDA has placed a U.S. clinical hold on the BX004 Phase 2b trial related to a third-party nebulizer; enrollment and dosing outside the U.S. continue and U.S. feedback is expected imminently. The company expects topline Phase 2b results in Q1 2026.
Financial highlights: cash and restricted cash $8.1M (Sept 30, 2025), sufficient to fund operations into Q1 2026; R&D $6.1M and G&A $2.4M in Q3; net loss $9.2M in Q3. Net cash used in operations was $22.0M for the nine months ended Sept 30, 2025.
BiomX (NYSE American: PHGE) will report third quarter 2025 financial results and program updates before U.S. market open on Wednesday, November 12, 2025. The company will host a conference call and live audio webcast at 8:30 AM ET to discuss results and program progress.
Registration is recommended at least 5 minutes before the call; the webcast will be live and archived on the company website.
BiomX (NYSE American: PHGE) received positive FDA feedback on the clinical development pathway for BX011, a fixed multi-phage cocktail targeting Staphylococcus aureus in diabetic foot infections (DFI), and plans a Phase 2a trial in DFI subject to funding.
The FDA support includes a path toward a potential BLA, no additional non‑clinical studies expected, and CMC comments consistent with BiomX’s manufacturing strategy. BX011 uses multiple proprietary phages, including one evaluated in the prior BX211 Phase 2 DFO study, which reported statistically significant topline ulcer-size reductions. BiomX has received about $40 million in non-dilutive U.S. defense funding for its S. aureus phage program.
BiomX (NYSE American: PHGE) provided a program update on BX004 and new FDA feedback on Oct 17, 2025. The company says it has responded to the FDA's limited technical clarifications about the third‑party nebulizer used to deliver BX004 and believes those queries are fully addressed. The FDA did not raise concerns about the BX004 drug product.
Key points: European enrollment and dosing continued ahead of plan; all European nebulizer components are CE marked; the Phase 2b study remains on track to report topline results in Q1 2026. The FDA also provided written feedback recognizing unmet need in chronic Pseudomonas aeruginosa infection and outlined potential Phase 3 enrichment and development pathways.
BiomX (NYSE American: PHGE) announced that CEO Jonathan Solomon will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8th, 2025, from 4:30 - 5:00 PM ET at the Lotte New York Palace Hotel in New York City.
The presentation, titled "Phage Therapy: A Novel Approach to Chronic Diabetic Foot Infections," will highlight the positive topline results from the company's Phase 2 trial of BX211 for treating Diabetic Foot Osteomyelitis (DFO). Investors can request one-on-one meetings through H.C. Wainwright representatives.
BiomX (NYSE American: PHGE) announced that the FDA has placed a clinical hold on the Phase 2b trial of BX004, their cystic fibrosis treatment. The hold specifically concerns the third-party nebulizer device used for drug delivery, with no issues raised about the BX004 drug candidate itself.
The company has already submitted additional requested data from the nebulizer manufacturer to the FDA. While U.S. patient screening and enrollment are temporarily paused, the European trial continues unaffected as the nebulizer components are CE marked and meet EU regulatory requirements.
BiomX (NYSE American: PHGE) reported significant clinical progress and Q2 2025 financial results. The company achieved positive Phase 2 results for BX211 in diabetic foot osteomyelitis, demonstrating >40% wound size reduction versus placebo. Their BX004 program showed promising results with a ~500-fold bacterial reduction in cystic fibrosis patients, as published in Nature Communications.
The company has initiated patient dosing in the Phase 2b trial of BX004, with topline results expected in Q1 2026. Financial highlights include a cash balance of $15.2 million as of June 30, 2025, with funding runway into Q1 2026. Q2 2025 showed reduced operating expenses, with R&D expenses at $5.0 million (down from $6.9M) and net loss of $6.0 million.
BiomX (NYSE American: PHGE), a clinical-stage company focused on developing phage therapies targeting specific pathogenic bacteria, has scheduled its second quarter 2025 financial results and program updates announcement for August 13, 2025, before U.S. markets open.
The company will host a conference call and audio webcast at 8:00 AM ET on the same day. Participants are advised to register at least 5 minutes before the call begins. Those not planning to ask questions are encouraged to join via the webcast, which will be available both live and archived in the Investors section of BiomX's website.
BiomX (NYSE American: PHGE) has initiated patient dosing in its Phase 2b trial of BX004, a phage therapy targeting antibiotic-resistant Pseudomonas aeruginosa infections in cystic fibrosis patients. The randomized, double-blind, placebo-controlled study will evaluate approximately 60 patients over an 8-week treatment period.
The trial follows promising Phase 1b/2a results where 14.3% of patients achieved complete bacterial clearance after just 10 days of treatment. The company expects topline results in Q1 2026 and anticipates FDA feedback in H2 2025 regarding the use of real-world evidence linking bacterial reduction to clinical outcomes. BX004 has already received Fast Track and Orphan Drug designations.